Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Investing.com - Lifevantage (NASDAQ: LFVN) reported first quarter EPS of $0.170, $0.01 better than the analyst estimate of $0.160. Revenue for the quarter came in at $55.1M versus the consensus estimate of $56.88M.
Guidance
Lifevantage sees FY 2026 EPS of $1.000-$1.150 versus the analyst consensus of $0.830.
Lifevantage sees FY 2026 revenue of $225.000M-$240.000M versus the analyst consensus of $231.300M.
Lifevantage’s stock price closed at $13.41. It is up 7.110% in the last 3 months and up 49.000% in the last 12 months.
Lifevantage saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Lifevantage’s stock price’s past reactions to earnings here.
According to InvestingPro, Lifevantage’s Financial Health score is "great performance".
Check out Lifevantage’s recent earnings performance, and Lifevantage’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar